EPI-743 for Mitochondrial Respiratory Chain Diseases

Summary

This study will evaluate the safety and efficacy of EPI-743 in participants with severe mitochondrial respiratory chain diseases who are considered to be within 90 days of end-of-life care.

Timeline

Start

—

Primary completion

—

Completion

—

Drugs

Indications